Avidity Biosciences Inc (NASDAQ: RNA) kicked off on Friday, down -15.59% from the previous trading day, before settling in for the closing price of $49.97. Over the past 52 weeks, RNA has traded in a range of $5.68-$56.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 148.90% over the last five years. While this was happening, its average annual earnings per share was recorded 2.65%. With a float of $108.62 million, this company’s outstanding shares have now reached $119.31 million.
The firm has a total of 253 workers. Let’s measure their productivity. In terms of profitability, gross margin is 80.79%, operating margin of -3209.35%, and the pretax margin is -2772.45%.
Avidity Biosciences Inc (RNA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Avidity Biosciences Inc is 7.24%, while institutional ownership is 101.07%. The most recent insider transaction that took place on Nov 06 ’24, was worth 4,843,979. In this transaction Chief Financial Officer of this company sold 106,319 shares at a rate of $45.56, taking the stock ownership to the 94,093 shares. Before that another transaction happened on Nov 06 ’24, when Company’s Officer proposed sale 106,319 for $45.09, making the entire transaction worth $4,793,924.
Avidity Biosciences Inc (RNA) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 2.65% per share during the next fiscal year.
Avidity Biosciences Inc (NASDAQ: RNA) Trading Performance Indicators
Take a look at Avidity Biosciences Inc’s (RNA) current performance indicators. Last quarter, stock had a quick ratio of 17.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 419.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.90, a number that is poised to hit -0.76 in the next quarter and is forecasted to reach -3.07 in one year’s time.
Technical Analysis of Avidity Biosciences Inc (RNA)
Analysing the last 5-days average volume posted by the [Avidity Biosciences Inc, RNA], we can find that recorded value of 1.81 million was better than the volume posted last year of 1.32 million. As of the previous 9 days, the stock’s Stochastic %D was 46.12%. Additionally, its Average True Range was 3.32.
During the past 100 days, Avidity Biosciences Inc’s (RNA) raw stochastic average was set at 28.65%, which indicates a significant increase from 7.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 98.28% in the past 14 days, which was higher than the 66.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $45.26, while its 200-day Moving Average is $34.39. Now, the first resistance to watch is $47.72. This is followed by the second major resistance level at $53.26. The third major resistance level sits at $56.20. If the price goes on to break the first support level at $39.24, it is likely to go to the next support level at $36.30. Now, if the price goes above the second support level, the third support stands at $30.76.
Avidity Biosciences Inc (NASDAQ: RNA) Key Stats
The company with the Market Capitalisation of 4.25 billion has total of 119,309K Shares Outstanding. Its annual sales at the moment are 9,560 K in contrast with the sum of -212,220 K annual income. Company’s last quarter sales were recorded 2,340 K and last quarter income was -80,400 K.
